Olin Biotech announced that Chen Aimin, director and deputy general manager, holds 5481,000 shares of the company, accounting for 0.14% of the company's total share capital. Due to personal capital requirements, it is proposed to reduce his holdings by no more than 137,000 shares through centralized bidding or bulk transactions, accounting for no more than 0.0338% of the company's total share capital. The reduction period is from September 22, 2026 to December 21, 2026.

Olin Biotech announced that Chen Aimin, director and deputy general manager, holds 5481,000 shares of the company, accounting for 0.14% of the company's total share capital. Due to personal capital requirements, it is proposed to reduce his holdings by no more than 137,000 shares through centralized bidding or bulk transactions, accounting for no more than 0.0338% of the company's total share capital. The reduction period is from September 22, 2026 to December 21, 2026.